Clinical trials: Male
Diabetes Mellitus
A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects
Primary Objective: To evaluate the effect of food on the single-dose pharmacokinetics of sotagliflozin relative to a fasted state in healthy adult male and female subjects.
- Trial name
- NCT03174548
- Testing
- Sotagliflozin (SAR439954)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Bladder Cancer
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
The purpose of this study is to explore a treatment that potentially enhances the delivery of chemotherapy to tumors in participants with superficial bladder cancer.
- Trial name
- NCT00318643
- Testing
- Mitomycin C, Chemophase
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Healthy
Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers
To establish the bioequivalence of fixed dose combination of 40 mg telmisartan / 12.5 mg HCTZ vs. its monocomponents
- Trial name
- NCT02262598
- Testing
- Telmisartan, Hydrochlorthiazide (HCTZ), Telmisartan/HCTZ fixed dose
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Rhinitis, Allergic, Seasonal
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects
This study is designed to assess the safety and tolerability of single, escalating oral doses and repeat oral doses (7 days, once daily) of GSK835726 in healthy male subjects
- Trial name
- NCT00605852
- Testing
- GSK835726
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms
Japanese BAY88-8223 Monotherapy Phase II Study
To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration
- Trial name
- NCT01929655
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 16 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Bayer
Castration-Resistant Prostatic Cancer
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life…
- Trial name
- PARABO (NCT02398526)
- Testing
- Radium-223 dichloride, (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Bayer
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2206 Injection vs Stelara® (EU-licensed and US-licensed) in healthy Chinese male…
- Trial name
- NCT04371185
- Testing
- BAT2206, Stelara(US-licensed), Stelara(EU-licensed)
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Healthy
Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions
This open-label, balanced, randomized, two-treatment, four-period, two-sequence, single dose, crossover fully replicated study was conducted on fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of…
- Trial name
- NCT00872235
- Testing
- fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Prostate Cancer
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or…
- Trial name
- NCT00286793
- Testing
- AT-101
- Where
- 13 sites in United States
- Volunteers
- 76 people
- Sponsor
- Ascenta Therapeutics
Hypertension
CKD-330 Drug-Drug Interaction Study (Candesartan)
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of Candesartan between free combination of Candesartan and Amlodipine and Candesartan monotherapy.
- Trial name
- CKD-330(C) (NCT02064621)
- Testing
- Candesartan 32mg, Candesartan 32mg/Amlodipine 10mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Urinary Incontinence, Stress
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
The purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.
- Trial name
- NCT00190814
- Testing
- duloxetine
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured patients (age >= 18 years and < 65 years).
- Trial name
- NCT01381614
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Renal Impairment
Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function
This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.
- Trial name
- NCT01372826
- Testing
- NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Common Cold
To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
This clinical study will be conducted to characterize the gastrointestinal transit of two multi-symptoms formulations by inclusion of a radiolabel marker.
- Trial name
- NCT03415243
- Testing
- Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration…
- Trial name
- NCT02918968
- Testing
- Enzalutamide, Flutamide, Androgen deprivation therapy
- Where
- 47 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Astellas Pharma Inc
End-stage Renal Disease (ESRD)
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
- Trial name
- NCT02553889
- Testing
- ISIS 416858
- Where
- 8 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- Trial name
- NCT02972268
- Testing
- Tamsulosin 0.2mg + Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 780 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.